中国临床药学杂志2025，Vol.34Issue(10)：743-748,6.DOI:10.19577/j.1007-4406.2025.10.004
新型抗肿瘤药物适应证审核系统在处方审核中的应用及效果评价
Application and effect evaluation of an indication review system for prescription review of novel antineoplastic agents
摘要
Abstract
AIM To establish a drug indication review system for novel antineoplastic agents and investigate its effectiveness and role in pre-prescription review.METHODS A system for reviewing indications of novel antineoplastic agents had been developed based on the hospital information system(HIS).The system performed pre-dispensing reviews of relevant prescriptions according to seven prescription review dimensions.All prescriptions of novel antineoplastic agents were collected from July to December 2021(before application)and from January 2022 to June 2023(after application).A comparative analysis of the rationality rate of prescription indications was conducted before and after the application of the system.In addition,an analysis of the quality control indexes of front-end auditing was conducted,as well as a breakdown of interception problems.RESULTS Prior to the introduction of the system,the reasonable rate of indications of outpatient prescriptions and inpatient medical orders was 83.76％and 95.70％,respectively.Following the implementation of the system,a notable increase in the reasonable rates of prescriptions and medical orders was observed in comparison to the previous rates(P＜0.001),which were 97.65％and 99.62％,respectively.The success rate of the intervention prior to the prescription and medical orders taking effect was 71.21％and 100％,respectively.The false-positive rates were 17.23％and 2.82％,and the false-negative rates were 0.92％and 0.38％.CONCLUSION The drug indication review system enhances the rationality rate of indications for novel antineoplastic agents during pre-prescription review and promotes rational drug use.关键词
新型抗肿瘤药物/适应证审核系统/智能化审核/处方前置审核/合理用药Key words
novel antineoplastic agents/indication review system/intelligent audit/pre-prescription review/rational drug use分类
药学引用本文复制引用
李键威,陈荣羡,张鑫,李伟恩,刘宝仪,伍炜培..新型抗肿瘤药物适应证审核系统在处方审核中的应用及效果评价[J].中国临床药学杂志,2025,34(10):743-748,6.基金项目
江门市医疗卫生领域科技计划项目(编号2022YL01083) （编号2022YL01083）
